More than 12 lawsuits have been filed on behalf of the weight loss drug users who claim that popular weight loss drugs such as Ozempic have caused vision loss.
Patients from New York and New Jersey argued that they had suffered neuropathy when they took drugs containing semi -grated, the active ingredients of Ozbig, Webby and Rebel Shus. This condition is rare and causes sudden loss of vision, including loss of blood flow to the optic nerve.
Jason Goldstein, a leader of the patient, said, “People are waking up and developing this state. News Day. “They wake up and can’t see it completely. Many people have lost their surroundings. They can lose their overall vision. I lost with both eyes to one customer.”
One of the 57 -year -old Edward Fanelli patients mentioned a warning of potential vision, saying, “If I was in the label, I would not have taken it.”
“Who is dangerous to lose your eyesight?” He asked.
New Jersey resident Fanelli began taking Ozempic to treat type 2 diabetes in October 2022 and was diagnosed with this state about eight months later. He could no longer work as a general contractor due to vision loss.
NOVO NORDISK, the producers of Ozempic and Wegovy, defended popular drugs. Lauren Browdy Weiner, a spokesman for drug manufacturers, said that this condition is not considered a side effect of the drug.
“Novo Nordisk says that Semaglutide’s benefits have not changed,” newsday said.
She said: “Patient safety is the top priority of Novo Nordisk, and we use all the reports on the side effects of drug use very seriously.
“This is also associated with eye condition, a well -known companionship for diabetics.”
Weiner noted that a research conducted by a drug manufacturer does not propose “causal relationship” between Semaglutide and the state.
On the other hand, external research concluded that more vision problems or weight loss drug patients are likely to increase, but more research is needed to truly understand the problem.
One study published in January at Jama Ophthalmology examined nine patients with vision complications in drugs, which are active ingredients of Semaglutide or Tirzepatide, active ingredients of mounjaro and zepbound. Seven of the nine patients have vision conditions.
Dr. Bradley Katz, the author of this study, said, “This review has not been done in a way that can say that these drugs have caused complications.”
He added: “We need further research to test our hypothesis. But this is an important issue for ophthalmologists when we monitor the use of these drugs and to communicate best with patients with patients.”
